<DOC>
	<DOC>NCT02030600</DOC>
	<brief_summary>This trial is conducted in the United States of America (USA). The aim of the trial is to compare the safety and efficacy of insulin degludec (IDeg) and insulin glargine (IGlar) with or without OADs (oral anti-diabetic drugs) excluding SUs (sulfonylureas)/glinides in subjects with type 2 diabetes.</brief_summary>
	<brief_title>A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, With or Without OADs in Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin, Long-Acting</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Male or female, age at least 18 years at the time of signing informed consent Subjects fulfilling at least one of the below criteria: a) Experienced at least one severe hypoglycaemic episode within last year (according to the ADA (American Diabetes Association) definition, April 2013), b) Moderate chronic renal failure, defined as glomerular filtration rate 30 59 mL/min/1.73 m^2 per CKDEpi (Chronic Kidney Disease Epidemiology Collaboration) by central laboratory analysis, c) Hypoglycaemic symptom unawareness, d) Exposed to insulin for more than 5 years, e) Recent episode of hypoglycaemia (defined by symptoms of hypoglycaemia and/or episode with low glucose measurement (below or equal to 70 mg/dL [below or equal to 3.9 mmol/L])) within the last 12 weeks prior to Visit 1 (screening) Type 2 diabetes mellitus (diagnosed clinically) for at least 26 weeks prior to Visit 1 Current treatment with any basal insulin (OD or BID) Â± any combination of OADs (metformin, DPP4 inhibitor, alphaglucosidase inhibitor, thiazolidinediones, and SGLT2inhibitor) for 26 weeks or longer prior to Visit 1 For subjects on BID the total daily dose should be below 75 units HbA1c (glycosylated haemoglobin) below or equal to 9.5 % by central laboratory analysis BMI (body mass index) below or equal to 45 kg/m^2 Treatment with a bolus insulin separately or contained in an insulin mix product within the last 26 weeks prior to Visit 1 Use of any other antidiabetic agent(s) than those stated in the inclusion criteria within the last 26 weeks prior to Visit 1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>